Peter S. Heeger
- PROFESSOR Medicine, Nephrology
M.D., University of Pennsylvania
- Dr. Heeger is Director of the Clinical Research Program in Transplantation Institute.
ResearchSpecific Clinical/Research Interest: Transplant immunology, complement, T cells
Postdoctoral Fellows: Wing Hong Kwan, PhD, Staci Leisman, MD, Deirdre Sawinski, MD
Research Personnel: Min Yang, PhD, Rajani Dinavahi, MD
I lead a basic science lab in transplant immunology and complement/T cell interactions. I am also the Director of Transplant Research at Mount Sinai and oversee all clinical and translational transplant trials at the institution. Our group leads a multicenter international NIH trial on biomarkers as predictors of transplant outcome
Summary of Research Studies:
The research performed in my laboratory focuses on understanding the cellular and molecular immunologic events involved in rejection and tolerance of allogeneic organ grafts in mouse models and in humans. Using mouse models we assess a) how and where alloreactive T cell recognize antigens found in transplanted donor tissues and b) which induced effector mechanisms are essential for inducing graft pathology. Recently published work from our group has also delineated a new link between innate and adaptive immunity by demonstrating that alternative pathway complement components influence the strength of all T cell immune responses, including those directed at allogeneic tissues. Lessons derived from the animal studies are being ''translated'' into humans. I direct an NIH U01 multicenter trial to assess the utility of noninvasive markers to predict outcome in organ transplant recipients. The study is designed to provide a rational scientific foundation for therapeutic decision-making aimed at maximizing graft survival and minimizing toxicity in organ graft recipients.
Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. C5a functions through T cell expressed C5aR to enhance T cell expansion by limiting T cell apoptosis. Blood 2008; 112: 1759-1766.
Augustine JJ, Poggio ED, Clemente M, Aeder MI, Bodziak KA, Schulak JA, Heeger PS, Hricik DE. Hemodialysis Vintage, African American Ethnicity, and Pretransplant Anti-donor Cellular Immunity in Kidney Transplant Recipients . J Am Soc Nephrol 2007; 18: 1602-1608.
Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay Accelerating Factor (DAF) can control T cell differentiation into interferon gamma producing effector cells via regulating local C5a-induced IL-12 production. Journal of Immunology 2007; 179: 5793-5802.
Poggio ED, Clemente M, Hricik DE, Heeger PS. Panel of reactive T cells (PRT) as a measure of cellular alloimmunity in kidney transplant candidates. J Am Society Nephr 2006;.
Heeger PS, Lin F, Lalli PN, Valujskikh A, Liu J, Ma Y, Medof ME. Decay Accelerating Factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530.
Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8 T cells mediate graft rejection via a distinct effector pathway. Nature Immunology 2002; 3: 844-851.
Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA, Tary-Lehmann M. Pretransplant frequency of donor-specific, interferon gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of post transplant kidney rejection episodes. J Immunol 1999; 163: 2267-2275.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Heeger during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Alexion Pharmaceuticals, Inc.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Cynvenio Biosystems, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 23rd Floor Room Room 66B
1468 Madison Avenue
New York, NY 10029